Solid Biosciences upsizes ATM equity facility to $200M; $85M already sold

Solid Biosciences Inc.

Filed prospectus supplement for up to $200M in common stock sales under existing ATM agreement with Jefferies.
Prior supplement for $85M exhausted; $85M in gross proceeds already raised.
New supplement replaces prior; no further sales under old supplement.
Legal opinion from WilmerHale attached as Exhibit 5.1.
Shares registered under existing shelf registration statement (S-3).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.